Cargando…
Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan
BACKGROUND: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. METHODS: We enrolled 59 RA patients treated with abatacept from a multicenter, exp...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171043/ https://www.ncbi.nlm.nih.gov/pubmed/34074293 http://dx.doi.org/10.1186/s12891-021-04392-5 |
_version_ | 1783702354954027008 |
---|---|
author | Kawashiri, Shin-ya Endo, Yushiro Nishino, Ayako Okamoto, Momoko Tsuji, Sosuke Takatani, Ayuko Shimizu, Toshimasa Sumiyoshi, Remi Koga, Tomohiro Iwamoto, Naoki Ichinose, Kunihiro Tamai, Mami Nakamura, Hideki Origuchi, Tomoki Aramaki, Toshiyuki Ueki, Yukitaka Yoshitama, Tamami Eiraku, Nobutaka Matsuoka, Naoki Okada, Akitomo Fujikawa, Keita Hamada, Hiroaki Nagano, Shuji Tada, Yoshifumi Kawakami, Atsushi |
author_facet | Kawashiri, Shin-ya Endo, Yushiro Nishino, Ayako Okamoto, Momoko Tsuji, Sosuke Takatani, Ayuko Shimizu, Toshimasa Sumiyoshi, Remi Koga, Tomohiro Iwamoto, Naoki Ichinose, Kunihiro Tamai, Mami Nakamura, Hideki Origuchi, Tomoki Aramaki, Toshiyuki Ueki, Yukitaka Yoshitama, Tamami Eiraku, Nobutaka Matsuoka, Naoki Okada, Akitomo Fujikawa, Keita Hamada, Hiroaki Nagano, Shuji Tada, Yoshifumi Kawakami, Atsushi |
author_sort | Kawashiri, Shin-ya |
collection | PubMed |
description | BACKGROUND: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. METHODS: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. RESULTS: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. CONCLUSION: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. TRIAL REGISTRATION: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-021-04392-5. |
format | Online Article Text |
id | pubmed-8171043 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81710432021-06-03 Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan Kawashiri, Shin-ya Endo, Yushiro Nishino, Ayako Okamoto, Momoko Tsuji, Sosuke Takatani, Ayuko Shimizu, Toshimasa Sumiyoshi, Remi Koga, Tomohiro Iwamoto, Naoki Ichinose, Kunihiro Tamai, Mami Nakamura, Hideki Origuchi, Tomoki Aramaki, Toshiyuki Ueki, Yukitaka Yoshitama, Tamami Eiraku, Nobutaka Matsuoka, Naoki Okada, Akitomo Fujikawa, Keita Hamada, Hiroaki Nagano, Shuji Tada, Yoshifumi Kawakami, Atsushi BMC Musculoskelet Disord Research Article BACKGROUND: To evaluate the effect of treatment on serum bone biomarkers and explore whether serum bone biomarkers are associated with therapeutic response in rheumatoid arthritis (RA) patients treated with abatacept. METHODS: We enrolled 59 RA patients treated with abatacept from a multicenter, exploratory, short-term, prospective and observational ultrasound cohort study of patients who received biologic or targeted synthetic disease-modifying antirheumatic drug (DMARD) therapy. We evaluated the patients’ clinical disease activity and musculoskeletal ultrasound (MSUS) scores. The serum concentrations of five bone biomarkers were evaluated (dickkopf-1 [Dkk-1], sclerostin [SOST], osteocalcin [OC], osteopontin [OPN], and osteoprotegerin [OPG]) by multiplex bead assays at baseline, 3, and 6 months: the change over 6 months was defined as the Δ value. ‘Power Doppler (PD) responder’ was defined as a patient whose Δtotal PD score over 6 months was greater than the median change. RESULTS: Abatacept significantly improved the clinical disease activity and MSUS score over 6 months. Serum OPG was significantly elevated at 6 months after the abatacept introduction (p = 0.016). The ΔSOST and ΔOPG were significantly greater in the PD responders versus the non-PD responders (p = 0.0041 and 0.0073, respectively). The serum Dkk-1 at baseline was significantly lower in the PD responders (n = 30) vs. the non-PD responders (n = 29) (p = 0.026). A multivariate logistic regression analysis showed that the serum Dkk-1 at baseline (odds ratio 0.50, 95% confidence interval [CI] 0.23–0.91, p = 0.043) was an independent predictor of PD responder status. CONCLUSION: Serum levels of bone biomarkers may be useful for predicting RA patients’ therapeutic responses to abatacept. TRIAL REGISTRATION: Name of the registry: Assessment of therapeutic responsiveness by imaging of the joints in patients with rheumatoid arthritis; A observational cohort study Trial registration number: UMIN000012524 Date of registration: 12/9/2013 URL of trial registry record: https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000014657 SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12891-021-04392-5. BioMed Central 2021-06-01 /pmc/articles/PMC8171043/ /pubmed/34074293 http://dx.doi.org/10.1186/s12891-021-04392-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Kawashiri, Shin-ya Endo, Yushiro Nishino, Ayako Okamoto, Momoko Tsuji, Sosuke Takatani, Ayuko Shimizu, Toshimasa Sumiyoshi, Remi Koga, Tomohiro Iwamoto, Naoki Ichinose, Kunihiro Tamai, Mami Nakamura, Hideki Origuchi, Tomoki Aramaki, Toshiyuki Ueki, Yukitaka Yoshitama, Tamami Eiraku, Nobutaka Matsuoka, Naoki Okada, Akitomo Fujikawa, Keita Hamada, Hiroaki Nagano, Shuji Tada, Yoshifumi Kawakami, Atsushi Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan |
title | Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan |
title_full | Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan |
title_fullStr | Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan |
title_full_unstemmed | Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan |
title_short | Association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (RA): a multicenter, prospective, and observational RA ultrasound cohort study in Japan |
title_sort | association between serum bone biomarker levels and therapeutic response to abatacept in patients with rheumatoid arthritis (ra): a multicenter, prospective, and observational ra ultrasound cohort study in japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8171043/ https://www.ncbi.nlm.nih.gov/pubmed/34074293 http://dx.doi.org/10.1186/s12891-021-04392-5 |
work_keys_str_mv | AT kawashirishinya associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT endoyushiro associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT nishinoayako associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT okamotomomoko associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT tsujisosuke associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT takataniayuko associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT shimizutoshimasa associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT sumiyoshiremi associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT kogatomohiro associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT iwamotonaoki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT ichinosekunihiro associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT tamaimami associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT nakamurahideki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT origuchitomoki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT aramakitoshiyuki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT uekiyukitaka associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT yoshitamatamami associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT eirakunobutaka associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT matsuokanaoki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT okadaakitomo associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT fujikawakeita associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT hamadahiroaki associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT naganoshuji associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT tadayoshifumi associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan AT kawakamiatsushi associationbetweenserumbonebiomarkerlevelsandtherapeuticresponsetoabataceptinpatientswithrheumatoidarthritisraamulticenterprospectiveandobservationalraultrasoundcohortstudyinjapan |